UBS Group Issues Pessimistic Forecast for Zentalis Pharmaceuticals (NASDAQ:ZNTL) Stock Price

Zentalis Pharmaceuticals (NASDAQ:ZNTL) had its target price reduced by investment analysts at UBS Group from $5.00 to $2.20 in a report issued on Tuesday,Benzinga reports. The firm presently has a “neutral” rating on the stock. UBS Group’s price objective would suggest a potential upside of 16.40% from the stock’s current price.

ZNTL has been the subject of several other reports. Guggenheim dropped their price objective on Zentalis Pharmaceuticals from $12.00 to $8.00 and set a “buy” rating for the company in a research report on Friday, November 15th. Wedbush reissued a “neutral” rating and issued a $4.00 price objective on shares of Zentalis Pharmaceuticals in a research note on Friday, January 24th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $20.00 target price on shares of Zentalis Pharmaceuticals in a research note on Friday, November 15th. Five equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $8.58.

Zentalis Pharmaceuticals Stock Down 21.3 %

Shares of ZNTL stock opened at $1.89 on Tuesday. Zentalis Pharmaceuticals has a 12-month low of $1.76 and a 12-month high of $18.07. The firm has a 50 day moving average price of $3.00 and a two-hundred day moving average price of $3.30. The company has a market capitalization of $134.68 million, a PE ratio of -0.76 and a beta of 1.86.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last posted its earnings results on Tuesday, November 12th. The company reported ($0.56) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.92) by $0.36. As a group, research analysts expect that Zentalis Pharmaceuticals will post -2.48 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of ZNTL. Erste Asset Management GmbH bought a new stake in Zentalis Pharmaceuticals during the 3rd quarter worth approximately $37,000. Paloma Partners Management Co purchased a new stake in shares of Zentalis Pharmaceuticals in the third quarter valued at about $37,000. Aigen Investment Management LP bought a new position in shares of Zentalis Pharmaceuticals during the third quarter valued at about $41,000. Capstone Investment Advisors LLC purchased a new stake in Zentalis Pharmaceuticals in the 3rd quarter valued at about $48,000. Finally, China Universal Asset Management Co. Ltd. lifted its position in shares of Zentalis Pharmaceuticals by 63.9% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 13,676 shares of the company’s stock worth $50,000 after buying an additional 5,333 shares in the last quarter.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.